Naprod Life Sciences Secures ANVISA GMP Certification Renewal for Oncology Manufacturing Operations
Key Insights
Naprod Life Sciences (search) successfully renewed its ANVISA GMP certification for its Tarapur manufacturing facility following a July 2025 inspection with no critical observations.
The certification enables continued manufacturing and supply of oncology (search) injectable and oral solid dosage products to Brazil, Latin America's largest pharmaceutical market.
The renewal strengthens Naprod's global regulatory portfolio alongside existing EU-GMP, PIC/S, and WHO-GMP approvals, facilitating market access across PIC/S-aligned Latin American countries.
Naprod Life Sciences (search) Pvt. Ltd. has successfully renewed its Good Manufacturing Practice (GMP) certification from ANVISA, Brazil's National Health Surveillance Agency, for its Tarapur manufacturing facility. The renewal follows a comprehensive regulatory inspection conducted in July 2025 that concluded with no critical observations, reinforcing the company's commitment to maintaining world-class quality standards.
Regulatory Inspection and Compliance
The ANVISA inspection thoroughly evaluated Naprod's oncology (search) injectable and oral solid dosage operations, examining the facility's manufacturing processes, quality systems, and compliance practices. The audit was conducted as part of ongoing partner-led regulatory requirements and assessed the company's ability to meet stringent international manufacturing standards.
The Tarapur facility operates as an integrated manufacturing site with dedicated oncology (search) and general blocks designed to produce liquid and lyophilized injectable formulations as well as solid oral dosage forms. This specialized infrastructure enables the company to manufacture complex oncology therapeutics while maintaining strict quality control measures.
Strategic Market Access
The certification renewal ensures Naprod's continued eligibility to manufacture and supply oncology (search) and select general therapeutic products to Brazil, which represents the largest pharmaceutical market in Latin America. This regulatory approval is crucial for the company's expansion strategy in the region.
"We are proud to continue our strong partnership with ANVISA, reaffirming our commitment to global regulatory excellence," said Mohan Jain, Managing Director of Naprod Life Sciences (search). "The renewal of our GMP certification is a testament to the high-quality systems, processes, and teams we have in place. Brazil is a strategic market for us, and this renewal supports our goal of expanding our presence while delivering high-quality oncology (search) and specialty products to our partners and patients."
Global Regulatory Portfolio Enhancement
The ANVISA GMP certification renewal strengthens Naprod's comprehensive global regulatory portfolio, which includes existing approvals such as EU-GMP, PIC/S, and WHO-GMP certifications. Brazil's membership in the Pharmaceutical Inspection Co-operation Scheme (PIC/S) provides additional strategic advantages, as the renewed approval facilitates access to other PIC/S-aligned markets throughout Latin America.
This regulatory milestone supports Naprod's broader growth strategy by enabling the commercialization of developed products, expansion of its international client base, and advancement of partnerships in manufacturing, co-development, and technology transfer. The certification is expected to improve speed-to-market capabilities in key regional markets.
Company Background and Capabilities
Established in 1994 and headquartered in Mumbai, Naprod Life Sciences (search) has developed into a leading Indian pharmaceutical company specializing in oncology (search) and anesthesia medications (search) for both domestic and international markets. The company's portfolio encompasses products for oncology, cardiovascular (search), anesthetic, anti-ulcerative (search), and anti-infective therapeutic areas.
Naprod primarily focuses on manufacturing and selling formulations and specialty injectables, with particular expertise in oncology (search) therapeutics. The company has built its reputation through excellence in innovation, discovery of new manufacturing processes, drug delivery mechanisms, and consistent commitment to quality standards across its operations.